Search research articles
Contact Us
Filters
Showing results (51-60 of 379) with videos related to
Page
of 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2005
Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab?
Alfredo Berruti, Daniele Generali, Maria Pia Brizzi, et al.
Trends in Endocrinology and Metabolism: TEM
|
January 29, 2021
Effects of Medical Treatment of Prostate Cancer on Bone Health
Anna Maria Formenti, Alberto Dalla Volta, Luigi di Filippo, et al.
Journal of the National Cancer Institute
|
February 20, 2003
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
Alfredo Berruti, Marcello Tucci, Carlo Terrone, et al.
JCEM Case Reports
|
August 1, 2025
Extraordinary Response to Mitotane Monotherapy in Advanced Aggressive Adrenocortical Carcinoma
Maria Elena Aloini, Pina Lardo, Roberta Maggio, et al.
Minerva Urology and Nephrology
|
February 11, 2022
Is adjuvant immunotherapy effective in patients with urothelial cancer?
Alberto Dalla Volta, Fausto Petrelli, Andrea Luciani, et al.
Endocrine
|
August 19, 2022
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
Irene Caramella, Alberto Dalla Volta, Marco Bergamini, et al.
Endocrine
|
June 4, 2020
Should everolimus be stopped after radiological progression in metastatic insulinoma? A "cons" point of view
Valeria Tovazzi, Vittorio D Ferrari, Alberto Dalla Volta, et al.
The Lancet. Oncology
|
February 4, 2006
Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation
Andrea Saini, Alfredo Berruti, Paola Sperone, et al.
Endocrine-Related Cancer
|
November 12, 2025
The role of 18F-FDG PET/CT in adrenocortical carcinoma: a systematic review
Domenico Albano, Salvatore Grisanti, Deborah Cosentini, et al.
Urology
|
September 5, 2013
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer
Orazio Caffo, Antonio Palermo, Antonello Veccia, et al.
Page
of 38
Search research articles
Search
Showing results (51-60 of 379) with videos related to
Sort By:
Page
of 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 2005
Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab?
Alfredo Berruti, Daniele Generali, Maria Pia Brizzi, et al.
Trends in Endocrinology and Metabolism: TEM
|
January 29, 2021
Effects of Medical Treatment of Prostate Cancer on Bone Health
Anna Maria Formenti, Alberto Dalla Volta, Luigi di Filippo, et al.
Journal of the National Cancer Institute
|
February 20, 2003
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
Alfredo Berruti, Marcello Tucci, Carlo Terrone, et al.
JCEM Case Reports
|
August 1, 2025
Extraordinary Response to Mitotane Monotherapy in Advanced Aggressive Adrenocortical Carcinoma
Maria Elena Aloini, Pina Lardo, Roberta Maggio, et al.
Minerva Urology and Nephrology
|
February 11, 2022
Is adjuvant immunotherapy effective in patients with urothelial cancer?
Alberto Dalla Volta, Fausto Petrelli, Andrea Luciani, et al.
Endocrine
|
August 19, 2022
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question
Irene Caramella, Alberto Dalla Volta, Marco Bergamini, et al.
Endocrine
|
June 4, 2020
Should everolimus be stopped after radiological progression in metastatic insulinoma? A "cons" point of view
Valeria Tovazzi, Vittorio D Ferrari, Alberto Dalla Volta, et al.
The Lancet. Oncology
|
February 4, 2006
Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation
Andrea Saini, Alfredo Berruti, Paola Sperone, et al.
Endocrine-Related Cancer
|
November 12, 2025
The role of 18F-FDG PET/CT in adrenocortical carcinoma: a systematic review
Domenico Albano, Salvatore Grisanti, Deborah Cosentini, et al.
Urology
|
September 5, 2013
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer
Orazio Caffo, Antonio Palermo, Antonello Veccia, et al.
Page
of 38